Ousia Pharma Secures Seed Funding to Revolutionize Obesity Treatment with Next-Gen Peptide Solutions

Ousia Pharma, a pioneering biotech spin-out from the University of Copenhagen, is proud to announce a new milestone in its journey toward revolutionizing obesity and metabolic disease treatments. In our latest funding announcement, we confirm that we have raised 0 USD in this round—a figure that underscores our continued focus on strategic partnerships, scientific collaboration, and the robust value of our proprietary research rather than immediate monetary support alone. Although the round has not involved external capital injections, this announcement reflects a deliberate approach to intensifying our internal investment in innovation, with team members and institutional backing further cementing our resolve. At the core of our mission is the development of novel peptide-drug conjugates that leverage a groundbreaking targeting approach: utilizing peptides to deliver modulators of synaptic plasticity, which drive potent and sustained weight loss without compromising safety. These innovations are designed to advance our lead weight loss drug candidate, OP-56, aimed specifically at tackling general obesity—a condition that continues to impact millions globally. The decision to focus on bolstering our research infrastructure rather than raising immediate external funds is part of a strategic plan to ensure that every step of our development process is underpinned by rigorous scientific evaluation and unwavering quality standards. As we move forward, Ousia Pharma remains dedicated to fostering strong collaborative relationships, accelerating research milestones, and ultimately transforming obesity treatment paradigms. We look forward to sharing further updates as our efforts pave the way for the next generation of metabolic health solutions.